Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management.

Moore, Donald C; Pellegrino, Annie E.
Ann Pharmacother; 51(9): 797-803, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28423916

Documentos relacionados

  1. Methadone versus Fentanyl in Patients with Radiation-Induced Nociceptive Pain with Head and Neck Cancer: A Randomized Controlled Noninferiority Trial.
  2. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
  3. Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.
  4. Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.
  5. Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer.
  6. Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial.
  7. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.
  8. Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report.
  9. Objective monitoring of nociception: a review of current commercial solutions.
  10. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.